CN116240152A - 一种鼠李糖乳杆菌sf-l30及其在制备清肺消炎产品中的应用 - Google Patents
一种鼠李糖乳杆菌sf-l30及其在制备清肺消炎产品中的应用 Download PDFInfo
- Publication number
- CN116240152A CN116240152A CN202310505972.5A CN202310505972A CN116240152A CN 116240152 A CN116240152 A CN 116240152A CN 202310505972 A CN202310505972 A CN 202310505972A CN 116240152 A CN116240152 A CN 116240152A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- lung
- heat clearing
- freeze
- oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims description 6
- 206010061218 Inflammation Diseases 0.000 title abstract description 15
- 230000004054 inflammatory process Effects 0.000 title abstract description 15
- 230000003467 diminishing effect Effects 0.000 title abstract description 13
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 240000000103 Potentilla erecta Species 0.000 claims abstract description 3
- 235000016551 Potentilla erecta Nutrition 0.000 claims abstract description 3
- 238000009629 microbiological culture Methods 0.000 claims abstract description 3
- 230000001580 bacterial effect Effects 0.000 claims description 26
- 238000000855 fermentation Methods 0.000 claims description 21
- 230000004151 fermentation Effects 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 18
- 235000013361 beverage Nutrition 0.000 claims description 16
- 229920001542 oligosaccharide Polymers 0.000 claims description 16
- 150000002482 oligosaccharides Chemical class 0.000 claims description 16
- 210000004072 lung Anatomy 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 11
- 238000009630 liquid culture Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 6
- 239000002054 inoculum Substances 0.000 claims description 4
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims description 3
- 239000001393 triammonium citrate Substances 0.000 claims description 3
- 235000011046 triammonium citrate Nutrition 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 235000015278 beef Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 abstract description 12
- 206010035664 Pneumonia Diseases 0.000 abstract description 7
- 208000023504 respiratory system disease Diseases 0.000 abstract description 5
- 239000006041 probiotic Substances 0.000 abstract description 3
- 235000018291 probiotics Nutrition 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 206010011224 Cough Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 230000004199 lung function Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101001099463 Mus musculus Myeloperoxidase Proteins 0.000 description 2
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 241001547127 Fritillaria cirrhosa Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 240000007171 Imperata cylindrica Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 241000287420 Pyrus x nivalis Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010971 suitability test Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及微生物技术领域，具体涉及一种鼠李糖乳杆菌SF‑L30及其在制备清肺消炎产品中的应用，该鼠李糖乳杆菌（Lactobacillus rhamnosus）SF‑L30保藏于中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC No.23780，保藏日期为2021年11月11日，保藏地址：北京市朝阳区北辰西路1号院3号。本发明提供的鼠李糖乳杆菌SF‑L30具有较强的胃肠适应能力，同时以鼠李糖乳杆菌SF‑L30为益生菌制得的清肺消炎产品，服用后可有效缓解肺部炎症，具有清肺消炎功能，减少呼吸道疾病发生。
Description
技术领域
本发明涉及微生物技术领域，具体涉及一种鼠李糖乳杆菌SF-L30及其在制备清肺消炎产品中的应用。
背景技术
呼吸系统疾病是一种气管、支气管、肺等部位的病变，多有咳嗽、痰多、气喘等症状，重者呼吸困难、缺氧，甚至呼吸衰竭致死。大气颗粒物、吸烟、工业经济发展导致的理化因子、生物因子，使慢性阻塞性肺疾病、支气管哮喘及肺部感染等疾病发生率有增无减。在临床实践中，相比于抗生素等抑菌药物，传统中医通过改善机体免疫，且毒副作用小受到广泛关注。中医学中认为，保持人体健康的核心动力是元气，而元气始于肺脏。清肺就是指清除堆积在肺脏里的有害物质和毒素，增强肺功能。研究表明，益生菌制剂可调节肺部感染，减少炎症因子随血液进入肺部。
CN03134278.7公布了一种适用于润肺生津养阴清热提高肺功能的饮料配方及方法，具有不加糖，舒适爽口的天然甜味，不加色具有亮丽的红棕色。有健脾益肾、润肺止咳、生津止渴，养阴清热之功能。CN201310313860.6 一种具有清肺功能组合物及制备方法，其由包括雪梨30-50份、橘红12-24份、茅根11-19份、花椰菜提取物7-13份、鱼腥草7-13份、动物血提取物7-13份、罗汉果4-6份、甜菊1.4-2.6份、甘草1.4-2.6份，该组合配方是一种适合广泛人群，清除肺泡污垢回复肺功能，预防呼吸系统疾病的保健饮品。CN201210114969.2公布了一种中药组合物在制备预防和改善肺部PM2.5沉积的药物中的应用，公开了中药组合物的有效成分的原料重量份组成为：枇杷叶6-8份，桔梗0.5-0.7份，水半夏1-3份，川贝母流浸膏0.6-0.8份，薄荷脑0.01-0.03份。本发明所述的中药组合物可以显著预防和改善肺部PM2.5沉积导致的肺功能下降和呼吸系统免疫损伤，是一种疗效确切、毒副作用小的中剂量中成药。以上专利均是采用中药药物机理清肺消炎，而现有技术中采用微生物发酵制剂治疗上述病症技术内容少见于记载。
发明内容
针对清肺消炎功能生物制品少、功效慢等技术问题，本发明提供一种鼠李糖乳杆菌SF-L30及其在制备清肺消炎产品中的应用，可有效缓解肺部炎症，具有清肺消炎功能，减少呼吸道疾病发生。
第一方面，本发明提供一种鼠李糖乳杆菌SF-L30，该鼠李糖乳杆菌（Lactobacillus rhamnosus）SF-L30保藏于中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC No. 23780，保藏日期为2021年11月11日，保藏地址：北京市朝阳区北辰西路1号院3号。
进一步的，鼠李糖乳杆菌SF-L30的培养方法为，将鼠李糖乳杆菌SF-L30接种于液体培养基，接种量为1%~2%，在37℃恒温下发酵18~24h，得到发酵液。
进一步的，液体培养基包括如下重量的组分：蛋白胨 10g、牛肉粉 5g、酵母粉 4g、K2HPO4·7H2O 2g、柠檬酸三铵 2g、葡萄糖 20g、CH3COONa·3H2O 5g、MgSO4·7H2O 0.2g、MnSO4·4H2O 0.05g、吐温80 1mL、蒸馏水 1000mL。
第二方面，本发明提供一种鼠李糖乳杆菌SF-L30在制备清肺消炎产品中的应用。
进一步的，清肺消炎产品为固体饮料、胶囊剂或咀嚼片。
进一步的，清肺消炎产品制备方法包括如下步骤：
（1）将鼠李糖乳杆菌SF-L30接种于液体培养基，接种量为1%~2%，在37℃恒温下发酵18~24h，获得发酵液；
（2）将发酵液置于离心机中离心，得到离心液，将离心液置于冻干机中冻干，获得冻干菌粉；
（3）将冻干菌粉与低聚糖混合制得成品。
进一步的，步骤（3）中，冻干菌粉与低聚糖质量比为1:5~9。
进一步的，步骤（3）中，低聚糖为低聚异麦芽糖、低聚果糖、低聚木糖中的一种或多种复配；当低聚糖为其中两种复配时，各成分质量比为1：1；当低聚糖为其中三种复配时，各成分质量比为1：1：1。
进一步的，清肺消炎产品中，鼠李糖乳杆菌SF-L30活菌数量为20亿CFU/g。每天人体摄入量为2~4g，摄入量在40亿-80亿CFU之间，如果摄入量较高则影响机体肠道菌群，产生不良影响；如低于总菌数则效果达不到预期。
本发明的有益效果在于，本发明提供的鼠李糖乳杆菌SF-L30具有较强的胃肠适应能力，同时以鼠李糖乳杆菌SF-L30为益生菌制得的清肺消炎产品，服用后可有效缓解肺部炎症，具有清肺消炎功能，减少呼吸道疾病发生。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案，下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍，显而易见地，对于本领域普通技术人员而言，在不付出创造性劳动的前提下，还可以根据这些附图获得其他的附图。
图1是测试例2中鼠李糖乳杆菌SF-L30对LPS诱导小鼠MPO影响数据柱状图。
具体实施方式
为了使本技术领域的人员更好地理解本发明中的技术方案，下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都应当属于本发明保护的范围。
如下使用的液体培养基包括如下重量的组分：蛋白胨 10g、牛肉粉 5g、酵母粉4g、K2HPO4·7H2O 2g、柠檬酸三铵 2g、葡萄糖 20g、CH3COONa·3H2O 5g、MgSO4·7H2O 0.2g、MnSO4·4H2O 0.05g、吐温80 1mL、蒸馏水 1000mL。
实施例1 鼠李糖乳杆菌SF-L30的分离和鉴定
1、菌源：酸奶，2021年1月采自青海省西宁市。
2、菌株的分离
对酸奶样品做十倍梯度稀释，每个梯度取100μL均匀涂布于MRS固体平板培养基上，随后取出置于厌氧罐中，37℃厌氧培养过夜；
次日可见平板上长有形态大小各异的菌落，挑取若干乳酸菌的特征菌落作二代划线纯化处理，平板厌氧活化1天，得培养物，随后做菌株鉴定。
3、鼠李糖乳杆菌SF-L30的鉴定
（1）鉴定单位
生工生物工程（上海）股份有限公司。
（2）引物序列
27F：5'-AGAGTTTGATCMTGGCTCAG-3'；
1492R：5'-GGTTACCTTGTTACGACTT-3'。
（3）鉴定的序列
TTGATTTAATTTTGAACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGATAACATTTGGAAACAGATGCTAATACCGCATAAATCCAAGAACCGCATGGTTCTTGGCTGAAAGATGGCGTAAGCTATCGCTTTTGGATGGACCCGCGGCGTATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCAATGATACGTAGCCGAACTGAGAGGTTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAAAACTCTGTTGTTGGAGAAGAATGGTCGGCAGAGTAACTGTTGTCGGCGTGACGGTATCCAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCTCGGCTTAACCGAGGAAGTGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAATGCTAGGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCTTTTGATCACCTGAGAGATCAGGTTTCCCCTTCGGGGGCAAAATGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATGACTAGTTGCCAGCATTTAGTTGGGCACTCTAGTAAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGATGGTACAACGAGTTGCGAGACCGCGAGGTCAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGTCGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTAACACCCGAAGCCGGTGGCGTAACCCTTTTA。
（4）鉴定结果
该菌株经生工生物工程（上海）股份有限公司鉴定为Lactobacillus（乳杆菌属），推测为Lactobacillus rhamnosus（鼠李糖乳杆菌）。
实施例2
将鼠李糖乳杆菌SF-L30按1%接种于液体培养基，在37℃恒温下发酵18h，得到发酵液，然后将发酵液置于离心机中离心，得到离心液，将离心液置于冻干机中冻干，得到冻干菌粉，然后与低聚木糖按1:9重量比例混合制备为固体饮料。
实施例3
将鼠李糖乳杆菌SF-L30按1%接种于液体培养基，在37℃恒温下发酵20h，得到发酵液，然后将发酵液置于离心机中离心，得到离心液，将离心液置于冻干机中冻干，得到冻干菌粉。然后将低聚异麦芽糖和低聚木糖按1:1重量比例制备低聚糖混合物，将冻干菌粉与低聚糖混合物按1:5重量比例混合制备为固体饮料。
实施例4
将鼠李糖乳杆菌SF-L30按1%接种于液体培养基，在37℃恒温下发酵22h，得到发酵液，然后将发酵液置于离心机中离心，得到离心液，将离心液置于冻干机中冻干，得到冻干菌粉。然后将低聚异麦芽糖和低聚果糖按1:1重量比例制备低聚糖混合物，将冻干菌粉与低聚糖混合物按1:5重量比例混合制备为固体饮料。
对比例1一种鼠李糖乳杆菌ACCC 10534制品
将鼠李糖乳杆菌ACCC 10534按1%接种于液体培养基，在37℃恒温下发酵18h，得到发酵液，然后将发酵液置于离心机中离心，得到离心液，将离心液置于冻干机中冻干，得到冻干菌粉，然后与低聚木糖按1:9重量比例混合制备为固体饮料。
对比例2一种鼠李糖乳杆菌ACCC 05450制品
将鼠李糖乳杆菌ACCC 05450按1%接种于液体培养基，在37℃恒温下发酵18h，得到发酵液，然后将发酵液置于离心机中离心，得到离心液，将离心液置于冻干机中冻干，得到冻干菌粉，然后与低聚木糖按1:9重量比例混合制备为固体饮料。
测试例1 鼠李糖乳杆菌SF-L30的胃肠液耐受性测试
（1）模拟胃液的配置：125mmol/L NaCl、7mmol/L KCl、45mmol/L NaHCO3和3g/L胃蛋白酶，用盐酸调节pH 2.5，制成模拟胃液，以0.22μm无菌滤膜过滤，现配现用；
（2）模拟肠液的配置：45mmol/L NaCl、1g/L胰蛋白酶、3g/L牛胆盐，用氢氧化钠调节pH 8.0，制成模拟肠液，以0.22μm无菌滤膜过滤，现配现用；
（3）分别将鼠李糖乳杆菌SF-L30、鼠李糖乳杆菌ACCC 10534、鼠李糖乳杆菌ACCC05450连续活化三代（每代18h），测定连续活化三代的菌株在A600下的OD值，通过计算求出OD5所需的菌液量；
（4）将OD5的菌液以8000G离心10min，弃上清，重悬于1mL模拟胃液中，37℃培养3h后进行平板活菌计数；
（5）取模拟胃液处理后的菌液8000G离心10min，弃上清，重悬于等体积的模拟肠液中，37℃培养4h后进行平板活菌计数。
按照如下公式计算各菌株的耐受胃肠液后的存活率，分析各菌株的胃肠道适应能力。
耐受胃肠液后的存活率（%）＝（耐受模拟肠液后菌液中的活菌数/菌液中的原始活菌数）×100%。
上述各菌株胃肠道适应性测试数据如表1所示。
表1 鼠李糖乳杆菌胃肠道适应性测试
结果如上表1所示，可以看出，鼠李糖乳杆菌ACCC 05450、鼠李糖乳杆菌ACCC10534的胃肠适应能力无显著差异，本发明鼠李糖乳杆菌SF-L30较其他鼠李糖乳杆菌胃肠适应能力强。
测试例2 鼠李糖乳杆菌SF-L30对LPS诱导小鼠肺炎的影响
将60只SPF级小鼠（体重18g-23g）饲喂7天，小鼠自由采食适应环境，然后随机分为6组，每组10只。然后腹腔注射20mg/kg LPS诱导小鼠肺炎，正常饲喂，在感染肺炎2小时后，按照如下方法进行饲喂。
对照组：每天口服生理盐水4ml一次，连续饲喂7天。
试验组1：每天灌服实施例2制备固体饮料4g，连续7天。
试验组2：每天灌服实施例3制备固体饮料4g，连续7天。
试验组3：每天灌服实施例4制备固体饮料4g，连续7天。
试验组4：每天灌服实对比例1制备固体饮料4g，连续7天。
试验组5：每天灌服实对比例2制备固体饮料4g，连续7天。
试验方法：摘眼球放血致死，将血液3000r/min离心10min收集血清，低温保藏，采用ELISA试剂盒检测TNF-α、IL-6含量水平。采用MPO检测试剂盒，取小鼠右肺称重后打碎匀浆后按照说明书标准检测流程对MPO活性进场分析： MPO活力=（测定OD值-对照OD值）/（11.3×取样量（g））。表2示出了鼠李糖乳杆菌SF-L30对LPS诱导小鼠TNF-α、IL-6的影响结果。图1为鼠李糖乳杆菌SF-L30对LPS诱导小鼠MPO的影响柱状图。
表2鼠李糖乳杆菌SF-L30对LPS诱导小鼠TNF-α、IL-6的影响
注：“▲”表示与对照组比较P＜0.05
结果分析：IL-6是活化的T细胞和成纤维细胞产生的淋巴因子，可作为炎症的标志物。TNF-α是炎症反应过程中出现最早、最重要的炎性介质。由表2可以看出，感染小鼠在仅仅服用生理盐水后，IL-6与TNF-α浓度明显偏高，其中试验组1浓度较对照组降低60%以上且具有显著差异（P＜0.05）。MPO在中性粒细胞中表达最丰富，中性粒细胞具有粘附、吞噬和杀菌作用，对机体抵抗病原菌起着重要的作用，本实验中，通过灌服本发明固体饮料，从图1可以看出，试验组与对照组相比MPO偏低，试验组1与对照组相比有显著差异（P＜0.05）。综上，通过服用本发明固体饮料，对小鼠炎症具有一定程度的改善效果。
可以表明，本发明的固体饮料在抑制LPS诱导小鼠肺炎方面具有良好的效果。
测试例3 鼠李糖乳杆菌SF-L30对咳嗽小鼠的影响
四周龄Hartley 雌性小鼠60 只，适应性7天饲喂，然后随机分为6组，每组10只。然后采用多用性智能实验动物气熏造模装置中以30只香烟烟熏30min，每日1次，连续10天。第11天开始，各组分开饲喂。对照组按照日常饲喂，每日灌服生理盐水4ml；试验组1、试验组2、试验组3、试验组4、试验组5分别每日灌服实施例2、实施例3、实施例4、对比例1、对比例2制备的固体饮料4g，连续10天。然后将小鼠分别放入诱咳引喘仪中雾化吸入1.0×10-4mmol/L浓度的辣椒素5min。从第一次咳嗽开始记录首次咳嗽时间和雾化吸入后5min内咳嗽次数。各组小鼠咳嗽潜伏期和咳嗽次数数据见表3。
表3各组小鼠咳嗽潜伏期和咳嗽次数的比较
注：▲表示与对照组比较P＜0.05
通过研究发现，本发明固体饮料能显著降低小鼠的咳嗽次数，并且能显著延后辣椒素引发的咳嗽发生时间，并且实施例2效果显著（P＜0.05）。
尽管通过参考附图并结合优选实施例的方式对本发明进行了详细描述，但本发明并不限于此。在不脱离本发明的精神和实质的前提下，本领域普通技术人员可以对本发明的实施例进行各种等效的修改或替换，而这些修改或替换都应在本发明的涵盖范围内/任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，可轻易想到变化或替换，都应涵盖在本发明的保护范围之内。
Claims (8)
1. 一种鼠李糖乳杆菌SF-L30，其特征在于，该鼠李糖乳杆菌（Lactobacillus rhamnosus）SF-L30保藏于中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC No. 23780，保藏日期为2021年11月11日，保藏地址：北京市朝阳区北辰西路1号院3号。
2.如权利要求1所述的鼠李糖乳杆菌SF-L30，其特征在于，鼠李糖乳杆菌SF-L30的培养方法为，将鼠李糖乳杆菌SF-L30接种于液体培养基，接种量为1%~2%，在37℃恒温下发酵18~24h，得到发酵液。
3. 如权利要求2所述的鼠李糖乳杆菌SF-L30，其特征在于，液体培养基包括如下重量的组分：蛋白胨 10g、牛肉粉 5g、酵母粉 4g、K2HPO4·7H2O 2g、柠檬酸三铵 2g、葡萄糖20g、CH3COONa·3H2O 5g、MgSO4·7H2O 0.2g、MnSO4·4H2O 0.05g、吐温80 1mL、蒸馏水1000mL。
4.一种权利要求1所述的鼠李糖乳杆菌SF-L30在制备清肺消炎产品中的应用。
5.如权利要求4所述的应用，其特征在于，清肺消炎产品为固体饮料、胶囊剂或咀嚼片。
6.如权利要求4所述的应用，其特征在于，清肺消炎产品制备方法包括如下步骤：
（1）将鼠李糖乳杆菌SF-L30接种于液体培养基，接种量为1%~2%，在37℃恒温下发酵18~24h，获得发酵液；
（2）将发酵液置于离心机中离心，得到离心液，将离心液置于冻干机中冻干，获得冻干菌粉；
（3）将冻干菌粉与低聚糖混合制得成品。
7.如权利要求6所述的应用，其特征在于，步骤（3）中，冻干菌粉与低聚糖质量比为1:5~9。
8.如权利要求6或7所述的应用，其特征在于，步骤（3）中，低聚糖为低聚异麦芽糖、低聚果糖、低聚木糖中的一种或多种复配；当低聚糖为其中两种复配时，各成分质量比为1：1；当低聚糖为其中三种复配时，各成分质量比为1：1：1。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310505972.5A CN116240152B (zh) | 2023-05-08 | 2023-05-08 | 一种鼠李糖乳杆菌sf-l30及其在制备清肺消炎产品中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310505972.5A CN116240152B (zh) | 2023-05-08 | 2023-05-08 | 一种鼠李糖乳杆菌sf-l30及其在制备清肺消炎产品中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116240152A true CN116240152A (zh) | 2023-06-09 |
| CN116240152B CN116240152B (zh) | 2023-07-04 |
Family
ID=86633440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310505972.5A Active CN116240152B (zh) | 2023-05-08 | 2023-05-08 | 一种鼠李糖乳杆菌sf-l30及其在制备清肺消炎产品中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116240152B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101575582A (zh) * | 2008-05-08 | 2009-11-11 | 景岳生物科技股份有限公司 | 具有抗炎活性的乳杆菌分离株及其用途 |
| CN102115721A (zh) * | 2008-05-08 | 2011-07-06 | 景岳生物科技股份有限公司 | 具有抗炎活性的乳杆菌分离株及其用途 |
| US20120020943A1 (en) * | 2010-07-20 | 2012-01-26 | China Medical University | Lactobacillus Plantarum and Uses Thereof |
| US20140065114A1 (en) * | 2012-08-29 | 2014-03-06 | China Medical University | Use of lactobacillus for liver protection |
-
2023
- 2023-05-08 CN CN202310505972.5A patent/CN116240152B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101575582A (zh) * | 2008-05-08 | 2009-11-11 | 景岳生物科技股份有限公司 | 具有抗炎活性的乳杆菌分离株及其用途 |
| CN102115721A (zh) * | 2008-05-08 | 2011-07-06 | 景岳生物科技股份有限公司 | 具有抗炎活性的乳杆菌分离株及其用途 |
| US20120020943A1 (en) * | 2010-07-20 | 2012-01-26 | China Medical University | Lactobacillus Plantarum and Uses Thereof |
| US20140065114A1 (en) * | 2012-08-29 | 2014-03-06 | China Medical University | Use of lactobacillus for liver protection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116240152B (zh) | 2023-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108208853B (zh) | 一种解酒护肝益生菌低聚肽复合制剂及制备方法 | |
| CN110835614B (zh) | 乳双歧杆菌gkk2、含其的组合物及其改善过敏性气喘的用途 | |
| KR20120133133A (ko) | 생약 추출물 또는 이의 유산균 발효물을 포함하는 호흡기 질환의 예방 또는 치료용 조성물 | |
| US11369648B2 (en) | Probiotic mixed preparation with anti-influenza ability and application thereof | |
| CN109628359A (zh) | 一株可缓解过敏性哮喘的罗伊氏乳杆菌及其应用 | |
| CN113913346B (zh) | 一种副干酪乳杆菌jn-1及其应用 | |
| KR101379404B1 (ko) | 황금 발효물 및 이를 포함하는 항균 및 면역 증강 조성물 | |
| CN114848685A (zh) | 抗过敏益生菌组合物及其应用、以及益生菌中药发酵物 | |
| LU502579B1 (en) | Bifidobacterium lactis for relieving constipation and application thereof | |
| CN111329884B (zh) | 植物乳杆菌bc299在炎症性肠病、精神性问题的药物、食品中的应用 | |
| CN109527099A (zh) | 一种枸杞复合益生菌羊奶片及其制备方法 | |
| CN116855413B (zh) | 利用鼠李糖乳杆菌YSs069制备调节人体微生态平衡的生物活性物质及其应用 | |
| CN116240152B (zh) | 一种鼠李糖乳杆菌sf-l30及其在制备清肺消炎产品中的应用 | |
| KR20200084829A (ko) | 나노화된 김치 유산균을 함유하는 항바이러스용 약학조성물 | |
| CN115607577B (zh) | 一种具有缓解口腔炎症功效的益生菌剂及其制备方法和应用 | |
| CN113975357B (zh) | 清肺化痰、消痈排脓、清热利湿的中药组合物及其应用 | |
| CN105535743A (zh) | 一种益生菌发酵型宣肺止咳合剂及其制备方法 | |
| CN116024129A (zh) | 一株能够与幽门螺杆菌共聚集的卷曲乳杆菌及其应用 | |
| CN113913330B (zh) | 一株调节OVA特异性IgE的植物乳杆菌及其应用 | |
| CN109674060B (zh) | 一种具有辅助缓解二型糖尿病功能的益生菌膳食补充剂及其应用 | |
| CN114164141B (zh) | 增强肺部功能的益生菌组合物及其制剂和应用 | |
| CN116606761B (zh) | 一种能够缓解类风湿性关节炎的动物双歧杆菌乳亚种BLa19及其应用 | |
| CN116875500B (zh) | 利用罗伊氏乳杆菌YSs207制备调节人体微生态平衡的生物活性物质及其应用 | |
| CN115005442B (zh) | 一种天山雪莲多糖提取物制备方法与应用 | |
| CN112029676B (zh) | 一种有利于提高免疫力的益生菌组合及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |